iBio has received notice that its shares fell below Nasdaq’s $1 minimum bid-price requirement for 30 consecutive business days. The notice does not immediately affect the stock’s listing: shares will continue trading on the Nasdaq Capital Market under the ticker IBIO while the company works to regain compliance.
The issue is a listing-standard deficiency, not an immediate change to iBio’s operations or ownership. The company says it is monitoring the share price and may use a reverse stock split if needed.
- Deadline to regain compliance: iBio has until May 18, 2027, to meet the requirement. It can do so by maintaining a closing bid price of at least $1 for 10 consecutive business days during that period. Nasdaq may require a longer run.
- Possible additional time: If iBio does not meet the requirement by May 18, it may qualify for another 180 days. To be eligible, it must satisfy Nasdaq’s other applicable listing standards, including the market-value requirement for publicly held shares, and tell Nasdaq in writing that it intends to address the shortfall—potentially through a reverse stock split.
- Delisting risk: If iBio does not regain compliance and is not eligible for the additional period, Nasdaq may move to delist its shares.
For now, the stock remains listed. A reverse split is one option iBio may consider, but the company has not said that it has decided to pursue one.
